PRESS RELEASE For immediate release Devonian Health Group announces completion of Enrollment in its Phase 2 Clinical Trial of Thykamine™ for the Treatment of mild-to-moderate Atopic Dermatitis in adult population. Last-patient-last-visit took place on June 3rd,...
Press Releases
Devonian Health Group Announces Change to its Board of Directors
PRESS RELEASE For immediate release Devonian Health Group Announces Change to its Board of Directors. QUEBEC, June 5, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused...
Devonian Health Group Announces an Exclusive Strategic Alliance with CannTx Life Sciences for the development of Cannabinoid-based Pharmaceutical Drugs
PRESS RELEASE For immediate release Devonian Health Group Announces an Exclusive Strategic Alliance with CannTx Life Sciences for the development of Cannabinoid-based Pharmaceutical Drugs. Combination of Devonian’s Botanical Drug expertise with CannTx Life...
Devonian Health Group Announces the nomination of Dr André P. Boulet to the American Botanical Drug Association
PRESS RELEASE For immediate release Devonian Health Group Announces the nomination of Dr André P. Boulet to the American Botanical Drug Association. Dr Boulet to represent Canada within the organization QUEBEC, May 21st, 2020 – Devonian Health Group Inc....
Devonian Health Group Announces the Closing of $1,805,000 Non-Brokered Financing
PRESS RELEASE For immediate release Devonian Health Group Announces the Closing of $1,805,000 Non-Brokered Financing. QUÉBEC CITY, May 4, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical...
Devonian Health Group Announces an Increase to its Non-Brokered Financing to $2,000,000
PRESS RELEASE For immediate release Devonian Health Group Announces an Increase to its Non-Brokered Financing to $2,000,000. QUÉBEC CITY, April 24, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical...
Devonian Health Group Announces the Issuance of Securities in Interest Settlement Due to Debenture Holders, a $330,000 Non-Brokered Financing and the Grant of Options
PRESS RELEASE For immediate release Devonian Health Group Announces the Issuance of Securities in Interest Settlement Due to Debenture Holders, a $330,000 Non-Brokered Financing and the Grant of Options. QUÉBEC CITY, April 22, 2020 – Devonian Health Group Inc....
Devonian Health Group Announces R-Spinasome® anti-aging technology global sales and marketing partnership
PRESS RELEASE For immediate release Devonian Health Group Announces R-Spinasome® anti-aging technology global sales and marketing partnership. QUEBEC, February 11, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage...
Devonian issues settlements of interest due to a debenture holder and announces the results of the annual general meeting of shareholders
PRESS RELEASE For immediate release DEVONIAN ISSUES SETTLEMENTS OF INTEREST DUE TO A DEBENTURE HOLDER AND ANNOUNCES THE RESULTS OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS. QUEBEC, – January 29, 2020 Devonian Health Group Inc. (“Devonian” or the...
Devonian Health Group Announces presentation to the World Conference on Ageing and Gerontology and a correction on expiry date of warrants
PRESS RELEASE For immediate release Devonian Health Group Announces presentation to the World Conference on Ageing and Gerontology and a correction on expiry date of warrants. QUEBEC, January 23, 2020 – Devonian Health Group Inc. (“Devonian” or the...